3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 4
2
Phase 3
2
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Completed
6
Terminated
3
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
INDIV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Retroperitoneal liposarcoma
1
Liposarcoma
1
Leiomyosarcoma
1
Chondrosarcoma
1
Interventions
Cyclophosphamide
37
Gemcitabine
31
Paclitaxel
27
Cisplatin
27
Carboplatin
27
Capecitabine
27
camrelizumab
24
Nivolumab
23
apatinib
22
Oxaliplatin
21
fludarabine
20
Radiotherapy
20
toripalimab
17
Immunotherapy, Adoptive
17
Drug Therapy
17
pembrolizumab
16
Docetaxel
16
Dexamethasone
15
Bevacizumab
15
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
14
Injections
14
tislelizumab
13
Temozolomide
13
Rituximab
13
Cetuximab
13
Irinotecan
12
130-nm albumin-bound paclitaxel
11
anlotinib
10
Fluorouracil
10
Trastuzumab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Unknown
×
nilotinib
×
Clear all
NCT02587169
2015-10-27
GEIS-27
Broto, Javier MartÃn, M.D.
Phase 1/2
Unknown
40 enrolled